Nicholas van As

Consultant Oncologist @royalmarsdenNHS Oncologist, Professor @ICR_London dad to 4, pretend cyclist (views my own)

[Nicholas van As @nickva1]

10 billion will buy some lovely horses 😊

[Dr Simon @DrSimonsTravels]

If I ever become a trillionaire, I’ll give 99% to good causes and buy a load of racehorses with the rest

Bookmark this tweet to remind me please

[Nicholas van As @nickva1]

Great data!

[Vedang Murthy @VedangMurthy]

Very proud of my whole team esp @indranilsays for brilliantly presenting the 1y AE data of the largest RCT in HR and N+ CaP.
SBRT is safe! Gr 3 AE very low.
More to follow....

[Nicholas van As @nickva1]

Great study @alison_tree and lovely presentation @DrSACooper

[Alison Tree 💙 @alison_tree]

Great presentation by @DrSACooper @ESTRO_RT showing low adverse events in both 5 and 2 fraction MRI-guided adaptive radiotherapy (HERMES trial), with minimal impact on quality of life in both arms.

[Alison Tree 💙 @alison_tree]

Great presentation by @DrSACooper @ESTRO_RT showing low adverse events in both 5 and 2 fraction MRI-guided adaptive radiotherapy (HERMES trial), with minimal impact on quality of life in both arms.

[Nicholas van As @nickva1]

Great talk! Well done @DrAPathmanathan

[Alison Tree 💙 @alison_tree]

Fantastic presentation by @DrAPathmanathan on PACE-NODES short term adverse events - more short lived GI events which settled quickly, no difference in GU events. Thanks to @ProstateUK for funding

[Alison Tree 💙 @alison_tree]

Fantastic presentation by @DrAPathmanathan on PACE-NODES short term adverse events - more short lived GI events which settled quickly, no difference in GU events. Thanks to @ProstateUK for funding

[Nicholas van As @nickva1]

Shared decision making requires a balanced discussion. RT techniques continue to reduce toxicity (more to do), data from TrueNTH, ProtecT/ PACE A highlight persistent incontinence and impotence after RP even with robotic techniques. Pts deserve honest evidence-based information.

[Nicholas van As @nickva1]

Interesting read! All radical treatments for pca have toxicities. The key issue for pts is not simply if toxicity occurs, but which toxicities persist and how they affect long-term QOL. Transient GU symptoms are not equivalent to permanent incontinence or impotence

[Nicholas van As @nickva1]

PACE-B and HYPO-RT-PC reported cumulative incidence AND point prevalence toxicity. Both matter. Cumulative incidence captures any event over time, while point prevalence reflects ongoing morbidity. Pt information should include duration, severity and reversibility of symptoms.

[UroToday.com @urotoday]

Optimal management of metachronous oligometastatic HSPC on PSMA PET. Presentation by @nickva1 @royalmarsdenNHS. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/0Gr9M0jDa6 @APCCC_Lugano

[ProstateUK Profs @ProstateUKProfs]

How have the PACE trials influenced radiotherapy treatment for #ProstateCancer to date?

Profs Emma Hall & @nickva1 at the ICR discuss learnings from a decade of trials, including @ProstateUK-funded PACE-NODES, in @IJROBP.

Grab a ☕ & read: https://t.co/QGgSPOJdnJ

[Nicholas van As @nickva1]

London Marathon 2026 https://t.co/3pTTYZZwxD My son Ollie is running the London Marathon to support the Royal Marsden. Please see link and support (particularly personal this year)

[CA: A Cancer Journal for Clinicians @CACancerJournal]

This 2025 review article, led by @DeepOnco of @royalmarsdenNHS, outlines global trends and the evolving diagnostics, treatment, and surveillance of #ProstateCancer: https://t.co/AUAGW1mzrM

@PCaParker @AmarUKishan @VedangMurthy @nickva1 @alison_tree @APCCC_Lugano @ICR_London

[Prof Suneil Jain @DrSuneil_PCa]

1166 patients with high risk prostate cancer randomised to prostate +/- pelvic nodes, 5 fraction radiotherapy. Early results hopefully presented later this year. Protocol and radiotherapy document online. @nickva1 @EmmaHall71 @DrAPathmanathan @alison_tree

[Nicholas van As @nickva1]

Fantastic visit! Such a pleasure to meet your brilliant team. Thanks for hosting me

[Vedang Murthy @VedangMurthy]

When Superstar 🌟 visitors like @nickva1 come to @RadOncTMC they have a fan base waiting for autograph on @NEJM paper on PACE-B as a souvenir.
Such a joy to have you here. Thanks for visiting @TataMemorial.

[Vedang Murthy @VedangMurthy]

When Superstar 🌟 visitors like @nickva1 come to @RadOncTMC they have a fan base waiting for autograph on @NEJM paper on PACE-B as a souvenir.
Such a joy to have you here. Thanks for visiting @TataMemorial.

[Nicholas van As @nickva1]

Thanks for coming. Great talk. Bring on #PACEpostop

[Federica Ferrario @Fefe_Ferrario]

Honoured to present an overview on post-op #SBRT for #PCa at #UKSABR25.
I truly loved the atmosphere — warm, inclusive, and incredibly supportive.
Grateful for the insightful discussions and for the wonderful people pushing SABR forward.
Until next time! 💙✨

@alison_tree

[Nicholas van As @nickva1]

Great talk! Interesting data. Well done @DrSACooper

[Alison Tree 💙 @alison_tree]

Great talk by @DrSACooper at #UKSABR2025 about the DESTINATION 1 trial of GTV dose escalation and whole gland de-escalation in localised prostate cancer. Clinical and dose papers out soon!

[Nicholas van As @nickva1]

@piet_ost @EORTC @gzaziekenhuizen @Mat_Guc @seanmmcbride @_ShankarSiva @DrewMoghanaki @rweichselbaum @DrOlsonOncology Great trial! Congrats